Company profile: Instil Bio
1.1 - Company Overview
Company description
- Provider of cell therapy solutions focused on tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers, advancing proprietary manufacturing expertise, technology, and data into clinical trials. Programs include a planned registrational study and a first-in-human next-generation engineered TIL, plus FRα CoStAR, a clinical-stage candidate for non-small cell lung cancer (NSCLC).
Products and services
- Next-Generation Engineered TIL Therapy: Instil Bio engineers tumor infiltrating lymphocytes for solid tumors, advancing a next-generation engineered program into a first-in-human study
- Proprietary TIL Manufacturing Technology and Data: Proprietary manufacturing expertise, technology, and data are advanced into clinical trials, enabling a planned registrational study with its candidate
- FRα CoStAR: Clinical-stage therapeutic candidate evaluated in clinical trials for non-small cell lung cancer (NSCLC), part of Instil Bio’s solid tumor cell therapy pipeline.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Instil Bio
Labopharm
HQ: Canada
Website
- Description: Provider of specialty pharmaceutical solutions that optimize the performance of existing drugs using advanced controlled-release technologies; operates internationally.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Labopharm company profile →
HRA Pharma
HQ: France
Website
- Description: Provider of drugs, devices, and services in reproductive health and endocrine diseases, offering products such as Norlevo for emergency contraception; Cicatridine for vaginitis and vaginal injury; Delidose, Divina, and Duova for hormone replacement therapy; and GyMiso for cervical ripening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HRA Pharma company profile →
Paion
HQ: Germany
Website
- Description: Provider of biopharmaceutical products; develops and commercializes drug candidates for diseases or interventions with substantial unmet medical need. Lead compound: remimazolam, an intravenous, ultra-short-acting, controllable benzodiazepine. Portfolio: Byfavo (procedural sedation, general anesthesia); Angiotensin II/GIAPREZA (refractory hypotension in septic or distributive shock); Eravacycline/XERAVA (complicated intra-abdominal infections in adults).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paion company profile →
PanGenetics
HQ: The Netherlands
Website
- Description: Provider of clinical development services for monoclonal antibodies targeting immune-mediated diseases, specializing in advancing candidates from late research stage through clinical proof of concept; based in Utrecht, the Netherlands, with an office in Cambridge, UK.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PanGenetics company profile →
AM-Pharma
HQ: The Netherlands
Website
- Description: Provider of biopharmaceutical therapeutics focused on inflammatory and infectious diseases, developing and commercializing products based on endogenous proteins, including ilofotase alfa, a recombinant alkaline phosphatase under development to prevent cardiac surgery-associated renal damage and as enzyme replacement therapy for hypophosphatasia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AM-Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Instil Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Instil Bio
2.2 - Growth funds investing in similar companies to Instil Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Instil Bio
4.2 - Public trading comparable groups for Instil Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →